Elanco Animal Health Management

Management criteria checks 2/4

Elanco Animal Health's CEO is Jeff Simmons, appointed in Jul 2018, has a tenure of 5.83 years. total yearly compensation is $13.66M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth €12.79M. The average tenure of the management team and the board of directors is 5.4 years and 5.2 years respectively.

Key information

Jeff Simmons

Chief executive officer

US$13.7m

Total compensation

CEO salary percentage	8.8%
CEO tenure	5.8yrs
CEO ownership	0.2%
Management average tenure	5.4yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeff Simmons's remuneration changed compared to Elanco Animal Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$14m	US$1m	-US$1b
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	n/a	n/a	-US$113m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$13m	US$1m	-US$78m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$171m
Mar 31 2022	n/a	n/a	-US$371m
Dec 31 2021	US$12m	US$1m	-US$483m
Sep 30 2021	n/a	n/a	-US$698m
Jun 30 2021	n/a	n/a	-US$729m
Mar 31 2021	n/a	n/a	-US$572m
Dec 31 2020	US$9m	US$1m	-US$574m
Sep 30 2020	n/a	n/a	-US$246m
Jun 30 2020	n/a	n/a	-US$101m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$16m	US$1m	US$68m
Sep 30 2019	n/a	n/a	US$94m
Jun 30 2019	n/a	n/a	US$144m
Mar 31 2019	n/a	n/a	US$45m
Dec 31 2018	US$5m	US$775k	US$87m
Sep 30 2018	n/a	n/a	-US$91m
Jun 30 2018	n/a	n/a	-US$172m
Mar 31 2018	n/a	n/a	-US$174m
Dec 31 2017	US$5m	US$688k	-US$311m

Compensation vs Market: Jeff's total compensation ($USD13.66M) is above average for companies of similar size in the German market ($USD3.35M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Simmons (56 yo)

5.8yrs

Tenure

US$13,663,169

Compensation

Mr. Jeffrey N. Simmons, also known as Jeff, serves as President and Chief Executive Officer at Elanco Animal Health Incorporated since July 2018 and its Director since September 2018. Mr. Simmons serves as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jeffrey Simmons	President	5.8yrs	US$13.66m	0.21% $ 12.8m
Todd Young	Executive VP & CFO	5.5yrs	US$3.73m	0.035% $ 2.2m
Ramiro Cabral	Executive Vice President of Elanco International	5.8yrs	US$2.65m	0.023% $ 1.4m
Ellen de Brabander	Executive Vice President of Innovation	2.6yrs	US$3.68m	0.0097% $ 599.7k
Timothy Bettington	Executive Vice President of Corporate Strategy & Market Development	1.2yrs	US$2.19m	0.017% $ 1.1m
James Meer	Senior VP & Chief Accounting Officer	5.7yrs	no data	0.0068% $ 419.4k
Chris Keeley	Senior VP & Chief Information Officer	no data	no data	no data
David Kinard	Executive Vice President of Human Resources	5.3yrs	US$2.85m	0.024% $ 1.5m
Katy Grissom	Head of Investor Relations	no data	no data	no data
Shiv O'Neill	Executive Vice President	1.3yrs	no data	0.0048% $ 298.6k
Larbi Lier	Senior Vice President of Asia	no data	no data	no data
Shabbir Simjee	Chief Medical Officer	no data	no data	no data

5.4yrs

Average Tenure

52yo

Average Age

Experienced Management: 5EA's management team is seasoned and experienced (5.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jeffrey Simmons	President	5.7yrs	US$13.66m	0.21% $ 12.8m
William Doyle	Independent Director	3.4yrs	US$330.01k	0.0030% $ 188.3k
Roy Hoover	Independent Chairman of the Board	5.7yrs	US$496.01k	0.060% $ 3.7m
Paul Herendeen	Independent Director	3.4yrs	US$330.01k	0.0020% $ 125.8k
Lawrence Kurzius	Independent Director	5.7yrs	US$350.01k	0.0020% $ 125.8k
Art Garcia	Independent Director	5yrs	US$330.01k	0.00072% $ 44.6k
Denise Scots-Knight	Independent Director	5.2yrs	US$330.01k	no data
John Paul Bilbrey	Independent Director	5.2yrs	US$346.01k	0.0085% $ 524.2k
Deborah Kochevar	Independent Director	5.2yrs	US$346.01k	0.00020% $ 12.4k
Kirk McDonald	Independent Director	5.2yrs	US$330.01k	no data
Michael Harrington	Independent Director	5.7yrs	US$330.01k	0.0033% $ 202.6k
Kapila Anand	Independent Director	5.7yrs	US$355.01k	0.00065% $ 40.3k

5.2yrs

Average Tenure

64.5yo

Average Age

Experienced Board: 5EA's board of directors are considered experienced (5.2 years average tenure).

Elanco Animal Health Management

Management criteria checks 2/4

Key information

Recent management updates

Elanco Animal Health Incorporated, Annual General Meeting, May 30, 2024

Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors

Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary

Elanco Animal Health Incorporated Announces Executive Changes

Insufficient new directors

President recently bought €135k worth of stock

Recent updates

Elanco Animal Health Incorporated, Annual General Meeting, May 30, 2024

Elanco Animal Health Incorporated to Report Q1, 2024 Results on May 08, 2024

Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors

Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary

Elanco Animal Health Incorporated Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$2.50 loss per share (vs US$0.16 loss in FY 2022)

Elanco Animal Health Incorporated to Report Q4, 2023 Results on Feb 26, 2024

Elanco Animal Health Incorporated Announces Executive Changes

Insufficient new directors

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Elanco Animal Health Incorporated Provides Financial Guidance for the Fourth Quarter 2023

New major risk - Revenue and earnings growth

Elanco Animal Health Incorporated to Report Q3, 2023 Results on Nov 07, 2023

Elanco Animal Health Incorporated(NYSE:ELAN) dropped from FTSE All-World Index (USD)

No longer forecast to breakeven

Elanco Animal Health Incorporated Launches Varenzin-CA1 (Molidustat Oral Suspension) - the First-Of-Its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.045 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.21 (vs US$0.098 in 1Q 2022)

Elanco Animal Health Incorporated Raises Earnings Guidance for the First Half and Full Year 2023

Forecast breakeven date pushed back to 2025

President recently bought €135k worth of stock

Independent Chairman of the Board recently bought €105k worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.97 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Elanco Animal Health Incorporated to Report Q4, 2022 Results on Feb 21, 2023

Elanco Animal Health Incorporated Announces FDA Approval of Bexacat(TM) (bexagliflozin tablets) -- the First-of-its Kind Oral Feline Diabetes Treatment Option

Independent Director recently bought €96k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.21 loss in 3Q 2021)

Elanco Animal Health Incorporated Provides Earnings Guidance for the Year 2022

Elanco Animal Health Incorporated to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €150k worth of stock

Scott Ferguson Steps Down from the Board of Directors of Elanco Animal Health Incorporated

Elanco Animal Health Incorporated Provides Earnings Guidance for Third Quarter of 2022

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.43 loss in 2Q 2021)

Elanco Animal Health Incorporated to Report Q2, 2022 Results on Aug 08, 2022

Independent Chairman of the Board recently bought €221k worth of stock

Independent Director recently bought €209k worth of stock

First quarter 2022 earnings released: EPS: US$0.098 (vs US$0.13 loss in 1Q 2021)

Elanco Animal Health Updates Guidance for the Full Year of 2022

Elanco Animal Health Incorporated to Report Q1, 2022 Results on May 09, 2022

Elanco Animal Health Incorporated, Annual General Meeting, May 18, 2022

Independent Chairman of the Board recently bought €260k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Elanco Animal Health Incorporated Provides Earnings Guidance for the First Quarter and Full Year of 2022

Elanco Animal Health Incorporated Announces Appointment of Rajeev (Bobby) Modi as its Executive Vice President U.S. Pet Health and Global Digital Transformation

TriRx Pharmaceutical Services, LLC acquired Elanco Manufacturing Facility in Speke from Elanco Animal Health Incorporated (NYSE:ELAN).

Elanco Adds New Tools to Advance U.S. Livestock Sustainability Efforts

Elanco Animal Health Incorporated to Report Q4, 2021 Results on Feb 24, 2022

Independent Chairman of the Board recently bought €261k worth of stock

Elanco Animal Health Incorporated Provides Earnings Guidance for the Fourth Quarter and Full Year 2021

Independent Chairman of the Board recently bought €139k worth of stock

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.29 loss in 3Q 2020)

President recently bought €426k worth of stock

Second quarter 2021 earnings released: US$0.43 loss per share (vs US$0.13 loss in 2Q 2020)

TriRx Pharmaceutical Services, LLC acquired Manufacturing site in Shawnee, Kansas from Elanco Animal Health Incorporated (NYSE:ELAN).

Elanco Animal Health Incorporated (NYSE:ELAN) entered into an agreement to acquire Kindred Biosciences, Inc. (NasdaqCM:KIN) for approximately $420 million.

TriRx Pharmaceutical Services, LLC entered into an agreement to acquire three manufacturing sites in Shawnee, Kan., and Speke, United Kingdom from Elanco Animal Health Incorporated (NYSE:ELAN).

Independent Chairman of the Board recently bought €666k worth of stock

Elanco Launches Product for U.S. Poultry Producers, Providing A Flexible Option for Cocci Control

Elanco Animal Health Incorporated Raises Earnings Guidance for the Full Year 2021

New 90-day high: €28.21

Executive VP, General Counsel & Corporate Secretary has left the company

Elanco Animal Health Incorporated Announces Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$1.27 loss per share (vs US$0.18 profit in FY 2019)

Revenue beats expectations